Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Smad6 shRNA
- Development stage
- Preclinical
- Lead developer
- Johns Hopkins University
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Smad6 shRNA is a short hairpin RNA (shRNA) therapeutic candidate designed to silence the expression of the SMAD6 gene. Smad6 is an inhibitory member of the Smad family that negatively regulates Bone Morphogenetic Protein (BMP) and Transforming Growth Factor-beta (TGF-β) signaling pathways. In pancreatic cancer, particularly in cases where SMAD4 is wild-type, Smad6 is frequently upregulated and acts as a pro-oncogenic factor by promoting cell proliferation, migration, and invasion. By utilizing RNA interference (RNAi) to reduce Smad6 protein levels, this shRNA construct aims to restore BMP signaling responsiveness and inhibit the metastatic progression of pancreatic adenocarcinoma. Research into Smad6 shRNA has primarily been conducted in preclinical models to validate Smad6 as a viable therapeutic target in SMAD4-intact pancreatic cancers.
- Other names
- shRNA targeting Smad6Smad6-targeting short hairpin RNASmad-6-targeting short hairpin RNASmad 6-targeting short hairpin RNA
02
Targets
SMAD7 (Mothers against decapentaplegic homolog 7)
Beyond the preview
Go deeper on Smad6 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Smad6 shRNA.